TCM
PTGX icon

Tuttle Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Tuttle Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-24,042
Closed -$313K – 212
2019
Q3 		$313K Buy
+24,042
New +$303K 0.08% 193

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Tuttle Capital Management's PTGX Position: Q4 2019 in Review

Tuttle Capital Management sold out of Protagonist Therapeutics (PTGX) in Q4 2019, closing a stake of 24,042 shares — an estimated $313K sold.

Tuttle Capital Management first reported a position in PTGX in Q3 2019 and held it in 1 quarter. The position peaked at $313K in Q3 2019. 81 funds tracked by Wall St. Rank hold PTGX as of Q4 2019.

  • Tuttle Capital Management reported no remaining Protagonist Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Tuttle Capital Management sold 24,042 Protagonist Therapeutics shares in Q4 2019, an estimated $313K.
  • Tuttle Capital Management first reported a position in Protagonist Therapeutics in Q3 2019 and held it in 1 quarter.
  • Tuttle Capital Management's Protagonist Therapeutics position peaked at $313K in Q3 2019.
  • 81 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2019.

Based on Tuttle Capital Management's 13F filing for Q4 2019, filed 13 Jan 2020.